GB SARS CoV-2 IgG
Qualitative ELISA for SARS-CoV-2 spike protein IgG antibody. 10 µL sample, 105-minute assay. Useful for assessing immune status post-vaccination or infection. 
PRODUCT DESCRIPTION
This in vitro diagnostic ELISA assay is designed for qualitative detection of IgG antibodies specific for the SARS-CoV-2 spike protein in human serum. It uses an indirect ELISA format on a 96-well microplate, requiring 10 µL of sample, with a total incubation time of 105 minutes and a 450 nm read wavelength. Storage at 2-8°C. Negative (Non-Reactive) results indicate no detectable IgG; positive (Reactive) results suggest presence of spike-protein IgG antibodies, to be interpreted alongside vaccine or infection history. 
SPECIFICATION
| Number of wells | 96 |
| Principle | Indirect |
| Assay format | Qualitative |
| Total incubation time | 105 minutes |
| Sample type | Serum |
| Sample volume | 10 μL |
| Reading wavelength | 450nm |
| Storage | 2-8°C |
| Certification | RUO |
PERFORMANCE
58 normal healthy patients with samples collected before COVID-19 outbreak were tested. The results are as follows：
The diagnostic sensitivity is 100%；The diagnostic specificity is 96.55%
| PERFORMANCE | Test Positive | Test Negative |
|---|---|---|
| Confirmed Positive | 0 | 58 |
| Confirmed Negative | 2 | 56 |
ORDERING INFORMATION
| Catalogue No. | Product |
|---|---|
| 4ECO101E | GB SARS-CoV-2 IgG – 96T |